Float Short %

0.61

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

EPS Last/This Y

-0.27

EPS This/Next Y

0.12

Price

1.4

Target Price

Analyst Recom

Performance Q

11.55

Relative Volume

0.04

Beta

0.54

Ticker: MNOV

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-09	MNOV	1.54	0.02	0.00	720
2025-12-10	MNOV	1.52	0.02	0.00	715
2025-12-11	MNOV	1.515	0.02	0.00	715
2025-12-12	MNOV	1.54	0.02	0.00	715
2025-12-15	MNOV	1.525	0.02	0.00	715
2025-12-16	MNOV	1.51	0.02	0.00	715
2025-12-17	MNOV	1.48	0.02	0.00	715
2025-12-18	MNOV	1.45	0.02	0.00	715
2025-12-19	MNOV	1.425	N/A	N/A	0
2025-12-22	MNOV	1.395	N/A	N/A	0
2025-12-23	MNOV	1.31	0.03	999.99	492
2025-12-26	MNOV	1.26	0.04	999.99	496
2025-12-29	MNOV	1.29	0.04	999.99	496
2025-12-30	MNOV	1.285	0.04	999.99	496
2025-12-31	MNOV	1.29	0.04	999.99	496
2026-01-02	MNOV	1.32	0.04	999.99	496
2026-01-05	MNOV	1.38	0.04	0.00	500
2026-01-06	MNOV	1.395	0.04	0.00	500
2026-01-07	MNOV	1.409	0.04	0.00	500
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

19 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-09	MNOV	1.54	-100.0	-	-0.50
2025-12-10	MNOV	1.51	-100.0	-	-0.50
2025-12-11	MNOV	1.51	-100.0	-	-0.50
2025-12-12	MNOV	1.54	-100.0	-	-0.50
2025-12-15	MNOV	1.52	-100.0	-	-0.50
2025-12-16	MNOV	1.52	-100.0	-	-0.50
2025-12-17	MNOV	1.48	-100.0	-	-0.50
2025-12-18	MNOV	1.45	-100.0	-	-0.50
2025-12-19	MNOV	1.41	-100.0	-	-0.50
2025-12-22	MNOV	1.40	-100.0	-	-0.50
2025-12-23	MNOV	1.32	-100.0	-	-0.50
2025-12-26	MNOV	1.27	-100.0	-	-0.50
2025-12-29	MNOV	1.29	-100.0	-	-0.50
2025-12-30	MNOV	1.29	-100.0	-	-0.50
2025-12-31	MNOV	1.30	-100.0	-	-0.50
2026-01-02	MNOV	1.32	-100.0	-	-0.50
2026-01-05	MNOV	1.39	-100.0	-	-0.50
2026-01-06	MNOV	1.39	-100.0	-	-0.50
2026-01-07	MNOV	1.40	-100.0	-	-0.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

19 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-09	MNOV	0.00	-0.11	1.22
2025-12-10	MNOV	0.00	-0.11	1.00
2025-12-11	MNOV	0.00	-0.11	1.00
2025-12-12	MNOV	0.00	-0.11	1.00
2025-12-15	MNOV	0.00	-0.11	1.00
2025-12-16	MNOV	0.00	-0.11	1.00
2025-12-17	MNOV	0.00	-0.11	1.00
2025-12-18	MNOV	0.00	-0.11	1.00
2025-12-19	MNOV	0.00	-0.11	1.00
2025-12-22	MNOV	0.00	-0.11	1.00
2025-12-23	MNOV	0.00	-0.11	1.00
2025-12-26	MNOV	0.00	-0.11	0.61
2025-12-29	MNOV	0.00	-0.11	0.61
2025-12-30	MNOV	0.00	-0.11	0.61
2025-12-31	MNOV	0.00	-0.11	0.61
2026-01-02	MNOV	0.00	-0.11	0.61
2026-01-05	MNOV	0.00	-0.11	0.61
2026-01-06	MNOV	0.00	-0.11	0.61
2026-01-07	MNOV	0.00	-0.11	0.61
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.06

Avg. EPS Est. Current Quarter

-0.12

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

-0.11

Beta

0.54

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-87.1

Target Price

P/E

Forward P/E

PEG

P/S

264.63

P/B

1.56

P/Free Cash Flow

EPS

-0.24

Average EPS Est. Cur. Y

-0.5

EPS Next Y. (Est.)

-0.38

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-4656.65

Relative Volume

0.04

Return on Equity vs Sector %

-54.4

Return on Equity vs Industry %

-39.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

MediciNova, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 13

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

stock quote shares MNOV – Medicinova Inc Stock Price stock today

news today MNOV – Medicinova Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch MNOV – Medicinova Inc yahoo finance google finance

stock history MNOV – Medicinova Inc invest stock market

stock prices MNOV premarket after hours

ticker MNOV fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: MNOV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y